Rocket Pharmaceuticals Intangible Assets

Rocket Pharmaceuticals's intangible assets stands at $25M as of March 2026. That compares with $25M in the prior-year period — up 0.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Rocket Pharmaceuticals reported $25M in intangible assets versus $25M a year earlier — essentially flat versus a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $25M in the prior-year period — up 0.0% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Rocket Pharmaceuticals's intangible assets evolved across reporting periods, while the comparison chart places RCKT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Rocket Pharmaceuticals's reading of $25M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.